WO2012109233A3 - Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein - Google Patents

Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein Download PDF

Info

Publication number
WO2012109233A3
WO2012109233A3 PCT/US2012/024133 US2012024133W WO2012109233A3 WO 2012109233 A3 WO2012109233 A3 WO 2012109233A3 US 2012024133 W US2012024133 W US 2012024133W WO 2012109233 A3 WO2012109233 A3 WO 2012109233A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
recurrence risk
breast cancer
cancer patients
predicting recurrence
Prior art date
Application number
PCT/US2012/024133
Other languages
English (en)
Other versions
WO2012109233A2 (fr
Inventor
Gordon B. Mills
Zhenlin JU
Kevin Coombes
Bryan HENNESSY
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012109233A2 publication Critical patent/WO2012109233A2/fr
Publication of WO2012109233A3 publication Critical patent/WO2012109233A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Abstract

L'invention concerne des procédés et des trousses utiles pour la prédiction ou l'estimation du risque de récidive chez un patient atteint d'un cancer du sein auquel on a administré ou que l'on a traité par un médicament anti-œstrogène. L'invention concerne des panels de marqueurs protéiques et des procédés d'utilisation des niveaux d'expression de ces marqueurs protéiques dans le calcul du risque de récidive du cancer et de la probabilité de réponse au traitement.
PCT/US2012/024133 2011-02-07 2012-02-07 Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein WO2012109233A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440213P 2011-02-07 2011-02-07
US61/440,213 2011-02-07

Publications (2)

Publication Number Publication Date
WO2012109233A2 WO2012109233A2 (fr) 2012-08-16
WO2012109233A3 true WO2012109233A3 (fr) 2012-10-04

Family

ID=46639155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024133 WO2012109233A2 (fr) 2011-02-07 2012-02-07 Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein

Country Status (1)

Country Link
WO (1) WO2012109233A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP2563936B1 (fr) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Méthodes et dispositifs permettant de prédire l'efficacité d'un traitement
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2016046640A2 (fr) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Procédés de prédiction de la réactivité à un médicament
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
US7569345B2 (en) * 2003-01-15 2009-08-04 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20100209920A1 (en) * 2002-03-13 2010-08-19 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209920A1 (en) * 2002-03-13 2010-08-19 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues
US7569345B2 (en) * 2003-01-15 2009-08-04 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMAD ET AL.: "Stromelysin 3: an independent prognostic factor for relapse-free survival in node- positive breast cancer and demonstration of novel breast carcinoma cell expression", AM. J. PATHOL., vol. 152, no. 3, March 1998 (1998-03-01), pages 721 - 728 *
STANWAY ET AL.: "Steroid sulfatase: a new target for the endocrine therapy of breast cancer", ONCOLOGIST, vol. 12, no. 4, April 2007 (2007-04-01), pages 370 - 374 *

Also Published As

Publication number Publication date
WO2012109233A2 (fr) 2012-08-16

Similar Documents

Publication Publication Date Title
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EP3208615A3 (fr) Utilisations d'inhibiteurs de hsp90 marqués
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2012006589A3 (fr) Procédés et compositions pour l'identification, l'évaluation et le traitement de cancers associés à des signaux hedgehog
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2012038068A8 (fr) Moyens et procédés pour la prévision de la réponse à un traitement d'un patient cancéreux
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
WO2012109233A3 (fr) Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
WO2012061683A3 (fr) Méthodes de traitement du cancer
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
WO2013083098A3 (fr) Procédé de détermination de la sensibilité médicamenteuse de cellules cancéreuses aux inhibiteurs de l'aurora kinase
WO2012170513A3 (fr) Thérapie à base de he4 pour une affection maligne
SG11201400919RA (en) Patient stratification and determining clinical outcome for cancer patients
SG11202103913WA (en) Method for quantifying molecular activity in cancer cells of a human tumour
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
WO2011066082A3 (fr) Marqueurs associés à l'anémie induite par la ribavirine
MX351945B (es) Mutantes c-raf que confieren resistencia a inhibidores raf.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12744652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12744652

Country of ref document: EP

Kind code of ref document: A2